The Quantum BioPharma Ltd. (QNTM) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer in the United States. Quantum BioPharma submits Form 6-K reports under the Securities Exchange Act of 1934, which include press releases, condensed consolidated interim financial statements, management’s discussion and analysis of financial condition and results of operations, material change reports, information circulars, and voting results. These documents give investors insight into the company’s biopharmaceutical activities in neurodegenerative and metabolic disorders and alcohol misuse disorders, as well as its capital markets and corporate actions.
Recent Form 6-K filings incorporate financial statements and MD&A for periods ended September 30, 2025, along with CEO and CFO certificates and related XBRL data. Other 6-Ks attach press releases covering topics such as clinical progress with Lucid-21-302 (Lucid-MS), at-the-market offering agreements, private placements, warrant expirations, and updates on the company’s digital asset portfolio. Additional filings include material change reports and management information circulars that document corporate decisions, shareholder meetings, and changes reported under Canadian securities rules but furnished to the SEC for U.S. investors.
Through these filings, users can review how Quantum BioPharma describes its lead MS program, licensing arrangements for unbuzzd , strategic investments via FSD Strategic Investments Inc., and litigation-linked contingent value rights (CVRs). The filings also reference the company’s registration statement on Form F-3, into which certain 6-K exhibits are incorporated by reference. On Stock Titan, these documents are updated from EDGAR in near real time and are accompanied by AI-powered summaries that highlight key points from each report, helping readers quickly understand financial disclosures, clinical milestones, capital structure changes, and other material information without reading every page.
Investors can use this filings page to locate Quantum BioPharma’s quarterly financial information, narrative analysis, press releases furnished as exhibits, and other regulatory documents that together outline the company’s operations, risk factors referenced in its Canadian and U.S. disclosures, and the evolution of its MS, alcohol health, and investment activities.
Quantum BioPharma Ltd. said the U.S. District Court for the Southern District of New York consolidated its direct action with an investor-led class action and appointed Grant & Eisenhofer P.A. as lead counsel for the class action. Quantum’s action alleges CIBC and RBC and/or their customers used “spoofing” to manipulate its share price between January 1, 2020, and August 15, 2024; the class action alleges harm to shareholders who sold Quantum securities between January 6, 2021, and October 15, 2025. The company said consolidation and counsel appointment are procedural developments, not findings on the merits, liability or damages.
Separately, Quantum retains 19.48% of Unbuzzd as of June 30, 2026. Its agreement with Unbuzzd provides royalties of 7% of sales until payments to Quantum total $250 million, after which the rate becomes 3% in perpetuity. Quantum retains 100% of rights to develop similar products or alternative formulations for pharmaceutical and medical uses. Its wholly owned subsidiary Lucid is researching Lucid-MS, which the company says was shown to prevent and reverse myelin degradation in preclinical models.
Quantum BioPharma Ltd. (QNTM) entered into a Study Start-Up Agreement with Thermo Fisher Scientific’s clinical research business to implement the planned Phase 2 trial of Lucid-21-302 (Lucid-MS), following the company’s receipt of FDA clearance to proceed. The agreement covers study start-up activities and related clinical research services.
The randomized, double-blind, placebo-controlled study is planned to evaluate efficacy, safety and tolerability in people with progressive forms of multiple sclerosis, using clinical and radiological endpoints relevant to disease progression and biology. Quantum describes Lucid-MS as an investigational New Chemical Entity designed to inhibit demyelination; it says preclinical models showed prevention and reversal of measures of myelin degradation.
The release cites approximately 2.8 million people worldwide with MS and a projection that the MS therapeutics market will exceed $38 billion by 2030. Quantum also reports a 19.48% ownership interest in Unbuzzd as of June 30, 2026, and royalties of 7% of sales until payments total $250 million, then 3% in perpetuity. The company lists additional regulatory approvals, trial financing, site activation and patient recruitment among factors affecting trial progress.
Quantum Biopharma Ltd. (QNTM) is the issuer of the Class B Subordinate Voting Shares for which AdvisorShares Trust reported beneficial ownership of 400,378 shares, or 4.95% of the class. AdvisorShares Trust reported sole voting and dispositive power over 400,378 shares, with shared voting and dispositive power over zero shares. It identified its ownership as 5% or less of the class.
Quantum BioPharma Ltd. announced that its licensee, Unbuzzd Wellness Inc., appointed Michael Zapolin as CEO. His stated mandate includes financing and listing Unbuzzd on a stock exchange, followed by a nationwide U.S. commercial marketing and product rollout. Former CEO Richard Buzbuzian is assisting with a transition to a publicly listed company that is scheduled to go effective in the next quarter.
Quantum said it retained 19.48% of Unbuzzd as of June 30, 2026, and the agreement provides royalties of 7% of sales until payments to Quantum total $250 million, after which the rate drops to 3% in perpetuity. Unbuzzd reported that a peer-reviewed clinical study found alcohol metabolism was more than 40% faster within 30 minutes, on average for most participants, and headache severity was reduced by 67% at four and eight hours. The product disclosure says individual results may vary and that health authorities have not evaluated or approved unbuzzd to diagnose, treat, cure or prevent disease.
Quantum BioPharma Ltd. (QNTM) reports audited 2025 results showing removal of a going-concern warning, stronger liquidity and reduced costs. Cash and digital assets were $11.3 million USD as of the filing date, and management states this provides a cash runway for basic operations through January 2028. For 2025, operating expenses fell to $15.3 million USD from $16.1 million, external R&D fees dropped to $2.8 million USD from $6.1 million, and trade and other payables declined from $4.1 million at December 31 2025 to $2.0 million.
To support funding, Quantum arranged a non-brokered private placement of up to 4,000 convertible debenture units at $1,000 each, carrying 1.25% monthly interest, convertible at $4.00 per share with warrants at $5.00; it also completed a fourth tranche of an earlier debenture offering and settled CAD$123,487.43 of debt by issuing 30,948 Class B shares at CAD$3.99. The company granted an aggregate of 580,192 options (including 7,692 to a director and 572,500 later in 2026) and is pursuing a small Class A multiple voting share placement to restore those shares’ voting power to about 75%. Pipeline updates include completion of Phase 1 and toxicology for Lucid‑MS, a peer‑reviewed clinical trial of unbuzzd™, and an ongoing equity and royalty interest in Unbuzzd Wellness Inc.
Quantum BioPharma Ltd. (QNTM) reports that investment bank Rodman & Renshaw has initiated analyst coverage on the company with a BUY rating and a US$8 price target. The company states this coverage is unpaid and that it provided no consideration or fees for the report.
Quantum describes itself as a biopharmaceutical company developing treatments for neurodegenerative and metabolic disorders and alcohol misuse, led by its preclinical multiple-sclerosis candidate Lucid-MS. Through its subsidiary and spin-out structure, Quantum also retains an equity interest and royalty rights in the consumer product UNBUZZD™.
Quantum BioPharma Ltd. (QNTM) reports that it will participate in the 3rd Annual ArcStone-Kingswood Growth Summit in Toronto on September 16, 2026, where Co-founder and Executive Co-chairman Anthony Durkacz will present recent milestones and future growth strategy to a curated investor audience.
The company highlights that the U.S. FDA has recently approved its Investigational New Drug application for Lucid-MS, enabling initiation of Phase 2 trials in patients with progressive multiple sclerosis, an area of substantial unmet need within a global MS therapeutics market anticipated to reach approximately US$38.62 billion by 2030. Quantum also reiterates its economic interest in UNBUZZD™, holding 19.48% of Unbuzzd Wellness Inc. as of June 30, 2026, and being entitled to a 7% sales royalty until cumulative payments reach $250 million, after which the royalty decreases to 3% in perpetuity, while retaining full rights to develop related pharmaceutical and medical formulations.
Quantum Biopharma Ltd. (QNTM) filed an amendment to its prior Form 6-K from April 2, 2026. The amendment’s sole purpose is to formally incorporate Exhibit 99.1, a press release dated April 2, 2026, into Quantum Biopharma’s existing Form F-3 registration statement (File No. 333-276264).
No other changes are made to the earlier Form 6-K; the press release is now deemed part of the Form F-3 from the date the original report was furnished, unless superseded by later filings.
Quantum Biopharma Ltd. (QNTM) filed an amended Form 6-K to change the treatment of a prior disclosure. The amendment specifies that Exhibit 99.1 from the Form 6-K furnished on April 1, 2026 is now incorporated by reference into the company’s Registration Statement on Form F-3 (File No. 333-276264).
The amendment makes no other changes to the earlier report and is a procedural step to ensure the April 1, 2026 press release forms part of the Form F-3 registration record, unless later superseded by subsequent filings.
Quantum Biopharma Ltd. (QNTM) furnishes Amendment No. 1 to a previously submitted Form 6-K from March 30, 2026. The amendment’s sole purpose is to have Exhibit 99.1, a press release dated March 30, 2026, formally incorporated by reference into the company’s Registration Statement on Form F-3 (File No. 333-276264).
The company states there are no other changes to the original Form 6-K beyond this incorporation-by-reference step.